Drugs / Elenestinib
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07388511 | Feb → Apr 2026 | — | Blueprint Medicines Corporation | Completed | No outcome recorded |
| Phase 1 | NCT05609942 | Sep 2023 → Jan 2025 | systemic mastocytosis | Blueprint Medicines Corporation | Terminated | No outcome recorded Stop: Business |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04910685 | Nov 2021 → Sep 2032 expected | Smouldering systemic mastocytosis | Blueprint Medicines Corporation | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Elenestinib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07388511 ↗ |
| Known as | BLU-263 | “elenestinib (BLU-263) + symptom directed therapy (SDT)” NCT04910685 ↗ |
| Modality | Small molecule | — CHEMBL5314552 ↗ |
| Route | Oral | “Elenestinib will be administered orally” NCT04910685 ↗ |